Merck & Co. Inc./Bayer AG's soluble guanylate cyclase stimulator vericiguat and Amgen Inc.'s novel inotropic molecule omecamtiv mecarbil, both in Phase III, are each projected to bring in over $1bn in chronic heart failure drug sales in major markets in 2026, accounting for more than one-fifth of total revenue for that year, according to a new pipeline review from Datamonitor Healthcare.
The chronic heart failure (CHF) market is dominated by generics; angiotensin receptor blockers (ARBs) and angiotensin converting
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?